Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

J Med Chem 2020 05 4;63(10):5102-5118. Epub 2020 Mar 4.

Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, ), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent target occupancy with an EC of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren's syndrome.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.9b01916DOI Listing
May 2020

Publication Analysis

Top Keywords

tyrosine kinase
12
covalent btk
12
autoimmune diseases
8
kinase selectivity
8
selective covalent
8
bruton's tyrosine
8
potent highly
8
highly selective
8
btk inhibitor
8
lou064 remibrutinib
8
remibrutinib potent
8
kinase
5
btk
5
tested phase
4
diseases demonstrates
4
suboptimal kinase
4
describe discovery
4
selectivity describe
4
based suboptimal
4
oncology indications
4

Similar Publications